BEIJING, Aug. 7, 2024
/PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord
Medical" or the "Company") (NYSE: CCM), a healthcare provider
specialized in cancer treatment, research, education and prevention
in China, today announced that it
has received a letter from the New York Stock Exchange ("NYSE")
dated August 6, 2024 (the "Compliance
Notice"), notifying the Company that it is no longer considered
below the NYSE's continued listing criterion of a minimum average
share price of US$1.00 over a 30
trading-day period (the "NYSE Minimum Price Requirement").
As previously announced, the Company received a letter from the
NYSE dated February 12, 2024, notifying the Company that it
was below compliance standards due to the trading price of its
American Depositary Shares. Following the receipt of the Compliance
Notice, the Company is no longer considered below the NYSE Minimum
Price Requirement, and has regained compliance regarding this
matter.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare
provider featuring a full cycle of premium oncology services
including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in
all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as
the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its
network of self-owned cancer hospitals and clinics as well as
partnered hospitals across China.
For more information, please see http://ir.ccm.cn.
About Concord Healthcare
Concord Healthcare is an oncology healthcare provider in
China. Concord Healthcare serves
both cancer patients through self-owned medical institutions and
third-party medical institutions through medical equipment,
software and related services. In its self-owned medical
institutions, Concord Healthcare provides a full spectrum of
oncology healthcare services to cancer patients across the entire
care continuum, leveraging its multidisciplinary team specialists
and diagnosis and treatment capabilities featuring precision
radiation therapy. Through its medical equipment, software and
related services, Concord Healthcare serves a widespread network of
enterprise customers, primarily hospitals, with integrated
oncology-related services, including primarily sales and
installing of medical equipment and software, management and
technical support, and operating lease.
Safe Harbor Statement
This announcement contains forward-looking statements. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties
and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are
subject to change. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. The Company does not undertake any
obligation to update any forward-looking statement, except as
required under applicable law.
View original
content:https://www.prnewswire.com/news-releases/concord-medical-regains-compliance-with-nyse-minimum-price-requirement-302216531.html
SOURCE Concord Medical Services Holdings Limited